T cells are the adaptive immune system’s first responders to any virus, circulating in the blood to detect and quickly multiply to attack the virus, and also support the development of antibodies by B cells. This central role for T cells makes them a desirable target for assessing the immune response to SARS-CoV-2 infection. In partnership with Microsoft, Adaptive Biotechnologies has created a comprehensive and detailed open access database, ImmuneCODE, that provides COVID-19 data to accelerate ongoing efforts to develop better diagnostics, vaccines, and therapeutics for COVID-19. Here we will discuss the science behind the ImmuneCODE database presented in Nolan et al, some of the applications for which you can analyze the data, use of the immunoSEQ T-MAP COVID service, and initial data insights from the COVID-19 data described in Snyder et al. Research Use Only. Not for use in diagnostic procedures.
1. A deep dive into the open-access ImmuneCODE database and the utility of the newly launched immunoSEQ T-MAP COVID service
2. Discussion of Nolan et al. and Snyder et al. publications
3. Initial data insights from COVID-19 data and how a blood-based molecular approach to characterizing the cellular immune response has applications in vaccine development as well as the potential to inform clinical diagnostics and monitoring